Context Therapeutics Inc. (NASDAQ:CNTX – Get Free Report) was the target of a large growth in short interest during the month of October. As of October 31st, there was short interest totalling 50,200 shares, a growth of 11.8% from the October 15th total of 44,900 shares. Based on an average trading volume of 35,600 shares, the short-interest ratio is presently 1.4 days. Approximately 0.4% of the shares of the stock are sold short.
Analyst Upgrades and Downgrades
Several equities analysts have commented on the company. Maxim Group started coverage on Context Therapeutics in a research report on Monday, September 11th. They issued a “buy” rating and a $4.00 target price for the company. HC Wainwright upgraded shares of Context Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 price objective for the company in a report on Wednesday, November 1st.
Institutional Investors Weigh In On Context Therapeutics
Context Therapeutics Price Performance
Shares of Context Therapeutics stock traded down $0.01 during trading on Friday, hitting $1.00. The company’s stock had a trading volume of 12,922 shares, compared to its average volume of 623,241. The stock has a market cap of $15.97 million, a price-to-earnings ratio of -0.78 and a beta of 2.51. Context Therapeutics has a 52 week low of $0.47 and a 52 week high of $1.69. The stock has a 50-day moving average price of $1.14 and a two-hundred day moving average price of $1.09.
Context Therapeutics Company Profile
Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors in the United States. It develops CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
- Five stocks we like better than Context Therapeutics
- 5 Top Rated Dividend Stocks to Consider
- 3 large caps with red hot RSIs with upside
- What is the NASDAQ Stock Exchange?
- Johnson Controls International: Nothing but upside for investors
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Unity Software’s resilient rebound post-earnings setback
Receive News & Ratings for Context Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Context Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.